Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 25;32(4):192.
doi: 10.3390/curroncol32040192.

New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2-Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III

Nicola Battelli  1 , Carmela Mocerino  2 , Michele Montedoro  3 , Mirco Pistelli  4 , Ilaria Portarena  5 , Mario Rosanova  6 , Tina Sidoni  7 , Patrizia Vici  8
Affiliations
Review

New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2-Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III

Nicola Battelli et al. Curr Oncol. .

Abstract

Early breast cancer (EBC) treatment has evolved from radical surgery to a multidisciplinary approach, integrating radiotherapy, chemotherapy, targeted therapy, and hormone therapy with surgery to ensure the best possible outcome. Despite these advancements, hormone receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) EBC still faces high recurrence rates after endocrine therapy. A panel of oncologists from Central-Southern Italy discussed the profile of ribociclib as an adjuvant therapy, based on the results of the NATALEE study, focusing on efficacy, safety, patient profiles, and regional challenges in treatment access. The experts identified ribociclib as suitable adjuvant treatment for stage II and III HR+/HER2- EBC patients, including those without lymph node involvement but with biologically aggressive disease. In their view, ribociclib could be an interesting option for patients not eligible for chemotherapy due to contraindications. Key challenges in translating the evidence on ribociclib in EBC into clinical practice include treatment duration, patient follow-up, and adverse events management. Strategies to address these challenges range from telemedicine and support from local clinics to tailored communication to improve adherence. Ribociclib is expected to significantly impact adjuvant treatment for HR+/HER2- EBC by addressing broader patient needs and potentially improving long-term outcomes through enhanced adherence and personalized management strategies.

Keywords: adherence; adjuvant therapy; breast cancer; ribociclib; stage II; stage III.

PubMed Disclaimer

Conflict of interest statement

Novartis organized the scientific board, and participants received a fee for their involvement in the board. The authors maintained full control over the content, and had final authority on all aspects of this article and did not receive any remuneration for their writing.

Figures

Figure 1
Figure 1
Possible factors defining the population where ribociclib adjuvant treatment could have the greater impact.
See this image and copyright information in PMC

References

    1. Jungles K.M., Holcomb E.A., Pearson A.N., Jungles K.R., Bishop C.R., Pierce L.J., Green M.D., Speers C.W. Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Front. Oncol. 2022;12:1022542. doi: 10.3389/fonc.2022.1022542. - DOI - PMC - PubMed
    1. Iqbal J., Ginsburg O., Rochon P.A., Sun P., Narod S.A. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313:165–173. doi: 10.1001/jama.2014.17322. - DOI - PubMed
    1. B.C Cancer Agency Breast Cancer Companion Guide. [(accessed on 10 June 2024)]; Available online: http://www.bccancer.bc.ca/patient-and-public-info-site/documents/compani....
    1. Ito M., Amari M., Sato A., Hikichi M., Sakamoto A., Yamazaki A., Saji S. Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy. Breast. 2024;73:103604. doi: 10.1016/j.breast.2023.103604. - DOI - PMC - PubMed
    1. Wangchinda P., Ithimakin S. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World J. Surg. Oncol. 2016;14:223. doi: 10.1186/s12957-016-0988-0. - DOI - PMC - PubMed

Publication types